Valuation
- Market cap
- 1,930,436,000
- Revenue TTM
- $0
- Net income TTM
- $-66,050,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 119,500
- Avg volume
- 433,000
- Day's range
- $20.58 – $21.53
- Shares out
- 90,039,000
- Stochastic %K
- 91%
- Beta
- —
- Analysts
- Strong Sell
- Price target
- $45.25
Company profile
Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM. The company was incorporated in 2024 and is headquartered in San Fr...
Show more
Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM. The company was incorporated in 2024 and is headquartered in San Francisco, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 415 707 6312
- Website
- https://www.braveheart.bio
- Address
- One Letterman Drive, Building A Suite A4-300, San Francisco, United States
Latest news
No headlines yet.
